Tag: release

Paris, July 22^nd, 2025

Paris, le 22 juillet 2025

WOODLAND PARK, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) announced today that it will hold a conference call on Wednesday, August 13, 2025, at 9:00 a.m. ET. Anterix senior management, led by President and CEO Scott Lang, will discuss the Company's first quarter fiscal 2026 results. A press release regarding the results will be issued after the close of the market on Tuesday, August 12, 2025.

Explore the future of the Germany IVD Analyzers market with our comprehensive report, covering key data from 2018 to 2033. Analyze segments like Hematology, PCR Systems, and POC Analyzers. Create winning strategies, understand market dynamics, and seize growth opportunities. Ideal for strategy development.

Le 22 juillet 2025                           

Geneva, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a bold strategic move to strengthen its position in the blockchain and post-quantum space. The company is establishing a cryptocurrency investment fund with a commitment of up to $30 million to invest in digital assets as part of its cryptocurrency treasury strategy.
This strategic allocation will directly support SEALSQ’s ongoing post-quantum cryptography initiatives, reinforcing its mission of enabling secure, decentralized infrastructures that are resilient to emerging quantum threats.

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

PARAMUS, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2025 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 4, 2025, before the New York Stock Exchange opens.

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.